Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The European market for PV devices is evolving, and new product launches backed by clinical evidence will allow for significant expansion through 2027.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for PV devices in Europe across a 10-year period.
Recently a meta-analysis was published that showed an increased risk of death associated with paclitaxel-coated balloons and stents after 2 years.
How will this study impact the European markets for DCBs and DES?
How has this study impacted physicians' perception of these products?
Which companies will be affected and how?
Peripheral DCBs have experienced strong growth in the years following their commercial launch.
To what degree will DCBs be adopted in Europe over the forecast period?
In which countries will DCBs see the fastest market growth?
Will DCBs or DES become the standard drug-eluting solution for BTK lesions?
How many competitors will enter the DCB market, and which will gain the most market share?
How will DCB uptake affect other PV devices such as stents, normal balloon catheters, and atherectomy devices?
Will the emergence of DCBs have an impact on recently established DES usage?
Which new indications will drive growth in the DCB market?
Recently, five-year analysis data were presented for Zilver PTX DES and IN.PACT DCBs.
What will be the impact of these long-term trials on adoption of DES and DCBs?
How will the IMPERIAL and BATTLE trials impact the use of Zilver PTX DCB?
Has Eluvia been able to gain shares in Europe due to impact of IMPERIAL trial?
DCBs and DES manufacturers have invested in clinical trials to expand their offerings in indications like BTK.
Which trials will impact the adoption of DCBs and DES for the BTK indication?
What has been physicians' preferred approach to treat lesions in the BTK indication?
Recently, CSI's Stealth 360 Peripheral Orbital Atherectomy System has received CE mark.
To what extent have atherectomy devices been adopted in Europe?
Will the newly launched Orbital Atherectomy System receive the same level of adoption in Europe that it has been receiving in the US?
Budgetary constraints continue to affect the European PV device market, especially in Italy.
What effect are GPOs having on the European PV device market?
How fast will ASPs erode and which countries will experience the greatest erosion?
How can companies mitigate this downward pressure in pricing?
Already a Client? Log in to access this report.
Ashish Bhupal is a team lead within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in clot managment, vascular access, aortic repair, heart valve, structural heart, and transcatheter embolization and occlusion device markets. Ashish holds a Bachelor's in Biotechnology and an MBA in Biotechnology Managment from Amity University, as well as a Six Sigma Green Belt certification from The British Standards Institution. Follow Ashish on Twitter: @Ashishb_DRG.